Psyence Biomedical (PBM) — Psyence Biomedical said its strategic partner PsyLabs produced a GMP-aligned ibogaine total-alkaloid extract that met microbial safety standards in third-party testing.
The milestone positions the company in the ibogaine supply chain amid rising US policy interest in ibogaine for addiction and veterans' mental health. It gives the small-cap a potential ingredient-supply angle for future clinical and research demand.
Source: globenewswire.com
For the rest of that week's sector news, read our week in review.